Since various targeted agents for inhibition of the VEGF axis and the PI3K-mTOR signaling pathway were approved for the systemic treatment of RCC, we tested the response of the anti-angiogenic drugs bevacizumab, sunitinib, and sorafenib and the mTOR inhibitor everolimus in our established RCC PDX cohort. Here, MTOR is linked to renal cell carcinoma.